Skip to main content

Advertisement

SpringerLink
Log in

Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5–7, 2012

  • Meeting Report
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abbreviations

1-MT:

1-Methyl tryptophan

AML:

Acute myeloid leukemia

ACT:

Adoptive cell therapy

AEs:

Adverse events

Haplo-HSCT:

Haploidentical hematopoietic stem cell transplantation

APC:

Antigen-presenting cells

APM:

Antigen processing and presentation machinery

B-NHLs:

B cell non-Hodgkin lymphoma

BLI:

Bioluminescence imaging

BM:

Bone marrow

CIC:

Cancer initiating cells

CSC:

Cancer stem cells

CTA:

Cancer–testis antigen

CEA:

Carcinoembryonic antigen

CCL:

Chemokine (C–C motif) ligand

CAR:

Chimeric antigen receptors

CLL:

Chronic lymphocytic leukemia

CRC:

Colorectal cancer cells

CREB:

cAMP response element-binding protein

CIK:

Cytokine-induced killer

CTLA-4:

Cytotoxic T-lymphocyte antigen 4

DC:

Dendritic cells

T-bodies:

Engineered T cells

EAP:

Expanded access program

GVHD:

Graft versus host disease

VH CDR3:

Heavy complementarity-determining region 3

HLA:

Human leukocyte antigen

hPSMA:

Human prostate-specific membrane antigen

HAS:

Human serum albumin

Ig:

Immunoglobulin

IDO:

Indoleamine 2,3-dioxygenase

isoDGR:

IsoAsp-Gly-Arg

KIR:

Killer cell immunoglobulin-like receptor

LAG-3:

Lymphocyte activation gene-3

LN:

Lymph node

MHC:

Major histocompatibility complex

MC:

Mast cells

MMP-9:

Metalloproteinase-9

mAb:

Monoclonal antibody

MM:

Multiple myeloma

MDSC:

Myeloid-derived suppressor cells

NK:

Natural killer

NSCLC:

Non-small-cell lung cancer

OS:

Overall survival

PBMC:

Peripheral blood mononuclear cell

PD-1:

Programmed cell death-1

PD-L1:

Programmed cell death-1 ligand 1

TGF:

Transforming growth factor

TRAMP:

Transgenic adenocarcinoma of the mouse prostate

TAA:

Tumor-associated antigen

TNF-alpha:

Tumor necrosis factor alpha

TCR:

T cell receptor

Treg:

Regulatory T cells

CD44v6:

Variant 6 of the adhesion receptor CD44

VEGF:

Vascular endothelial growth factor

Acknowledgments

This work was supported in part by grants from: Associazione Italiana per la Ricerca sul Cancro (Hugues Jean Marie Nicolay fellow) and Istituto Toscano Tumori. A special thanks to the NIBIT members and meeting speakers for their contribution to the manuscript and the conference.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Viale Mario Bracci n. 16, 53100, Siena, Italy

    Michele Maio, Hugues Jean Marie Nicolay, Giulia Parisi, Ornella Cutaia & Ester Fonsatti

  2. Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori Fondazione “G. Pascale”, Naples, Italy

    Paolo Antonio Ascierto

  3. Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy

    Filippo Belardelli

  4. Clinical Research, Sigma Tau S.p.A., Pomezia, Italy

    Roberto Camerini

  5. Molecular Immunology Unit, Department of Experimental Oncology, Fondazione Istituto Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy

    Mario Paolo Colombo

  6. Oncologia Medica A, IRCCS Ospedale San Martino-Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

    Paola Queirolo

  7. Immunotherapy and Somatic Cell Therapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Forlì, Italy

    Ruggero Ridolfi

  8. Cancer Gene Therapy Unit, Division of Molecular Oncology, San Raffaele Foundation Center, Milan, Italy

    Vincenzo Russo

  9. Unit of Immunobiotherapy of Melanoma and Solid Tumors, Division of Molecular Oncology, San Raffaele Foundation Centre, Milan, Italy

    Giorgio Parmiani

Authors
  1. Michele Maio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hugues Jean Marie Nicolay
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paolo Antonio Ascierto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Filippo Belardelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Roberto Camerini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mario Paolo Colombo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Paola Queirolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ruggero Ridolfi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Vincenzo Russo
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Giulia Parisi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Ornella Cutaia
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ester Fonsatti
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Giorgio Parmiani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michele Maio.

Additional information

This study was conducted on behalf of Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maio, M., Nicolay, H.J.M., Ascierto, P.A. et al. Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5–7, 2012. Cancer Immunol Immunother 62, 1851–1858 (2013). https://doi.org/10.1007/s00262-013-1496-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-013-1496-5

Keywords

Search

Navigation